| [1] |
Goldie J H,Goldman A J . A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate.Cancer Treat Rep,1979,63:1727 -1733.
|
| [2] |
Mieog J S, van der Hage J A, van de Velde C J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev,2007,18:CD005002.
|
| [3] |
Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide,methotrexate and fluorouraciland Its effects on tumor response as preoperative therapy. Clin Cancer Res,2005,11:8715 -8721.
|
| [4] |
Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.J Natl Cancer Inst Monogr,2001,30:96 -102.
|
| [5] |
Diéras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol,2004,22:4958 -4965.
|
| [6] |
Bear H D, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27.Journal of Clinical Oncology,2003,21:4165-4174.
|
| [7] |
Iwata H,Nakamura S,Toi M, et al.Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil(CEF) Followed by docetaxel as preoperative chemotherapy for early breast carcinoma.Breast Cancer,2005,12:99 -103.
|
| [8] |
Kuerer H M, Singletary S E, Buzdar A U, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg,2001,182:601 -608.
|
| [9] |
Newman L A, Buzdar A U, Singletary S E, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.Ann Surg Oncol,2002,9:228 -234.
|
| [10] |
Buchholz T A, Hunt K K, Whitman G J, et al. Neoadjuvant chemotherapy for breast carcinoma multidisciplinary considerations of benefits and risks.Cancer,2003,98:1150-1160.
|
| [11] |
NCCN. NCCN Clinical Practice Guidelines in Oncology-V. 2.2007.http/ /www.nccn.org
|
| [12] |
Helvie M A, Joynt L K, Cody R L, et al. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.Radiology,1996,198:327 -332.
|
| [13] |
Moyses B, Haegele P, Rodier JF, et al. Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer. Clin Breast Cancer,2002,2:304 -310.
|
| [14] |
Akashi Tanaka S,Fukutomi T,Watanabe T,et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer,2001,96:66 -73.
|
| [15] |
Boetes C, Strijk S P, Holland R, et al. False-negative MR imaging of malignant breast tumors. Eur Radiol, 1997,7:1231 -1234.
|
| [16] |
Abraham D C, Jones R C, Jones S E, et al . Evaluating of neoadjuvant chemoterhapeutic response of locally advanced breast cancer by magnetic resonace imaging. Cancer,1996,78:91 -100.
|
| [17] |
贾海霞,苏逢锡,郭巨江,等.乳腺癌新辅助化疗的坐标定位法.中华普外科杂志,2006,21:225 -226.
|
| [18] |
Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer:results in a large series.J Natl Inst,1999,91:368 -373.
|
| [19] |
Sabel M S, Schott A F,Kleer C G, et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg, 2003,186:102 -105.
|
| [20] |
Xing Y, Foy M, Cox D D, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.Am Soc Clin Oncol,2004,17:561 -564.
|
| [21] |
刘慧. 新辅助化疗在可手术乳腺癌的应用研(研究生论文).郑州:郑州大学,2004.
|
| [22] |
Buchholz T A, Tucker S L, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol,2002,20:17 -23.
|
| [23] |
Arens N, Bleyl U, Hildenbrand R. HER-2/neu, p53, Ki67,and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch, 2005,446:489 -496.
|
| [24] |
Eniu A, Carlson R W Aziz Z, Bines J, et al. Breast cancer in limited-resource countries:treatment and allocation of resources.Breast J,2006,12:38-53.
|